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It has been postulated that imprinting aberrations are common in tumors. To understand the
role of imprinting in cancer, we have characterized copy-number and methylation in over 280
cancer cell lines and confirm our observations in primary tumors. Imprinted differentially
methylated regions (DMRs) regulate parent-of-origin monoallelic expression of neighboring
transcripts in cis. Unlike single-copy CpG islands that may be prone to hypermethylation,
imprinted DMRs can either loose or gain methylation during tumorigenesis. Here, we show
that methylation profiles at imprinted DMRs often not represent genuine epigenetic changes
but simply the accumulation of underlying copy-number aberrations (CNAs), which is
independent of the genome methylation state inferred from cancer susceptible loci. Our
results reveal that CNAs also influence allelic expression as loci with copy-number neutral
loss-of-heterozygosity or amplifications may be expressed from the appropriate parental
chromosomes, which is indicative of maintained imprinting, although not observed as a single
expression foci by RNA FISH.
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Cancer is the leading cause of death in adults. Tumorsthemselves are typically classified using pathologicalcriteria and tissue origin. However following the huge
investment from large international consortia, cancers can
now be sorted into molecular subgroups based on genetic and
epigenetic profiles1 which has led to targeted therapies for
subtypes with specific alterations.
To help with molecular classification, we have investigated
whether aberrations at imprinted loci can stratify tumors from
different tissue origins.
Genomic imprinting is the parent-of-origin specific mono-
allelic transcription, regulated in part by allelic difference in
DNA methylation established in the male and female germline
and maintained throughout somatic development2. In addition
to being indispensible for growth, imprinted genes have been
suggested to play a crucial role in driving oncogenic switch
or suppressing tumor development3. Deregulated expression,
which includes the reactivation of the normally silent
allele (commonly referred to as loss-of-imprinting, LOI) or
the silencing of the transcribed allele, has been implicated in
childhood cancer associated with the classical imprinting disorder
Beckwith–Wiedemann syndrome4. In these cases gains of
methylation at the paternally methylated H19 DMR or paternal
uniparental disomy (copy-number neutral loss-of-heterozygosity,
cnnLOH) result in over-expression of IGF2-miR483 and the
concomitant silencing of H19-miR6755. However it is becoming
evident that an increasingly number of imprinted genes shows
irregularities in adult tumors. For example aberrant expression of
transcripts in the H19-IGF2 domain has been reported in more
than 15 tumor types, with somatic amplifications of IGF2 and
miR483 implicated in the initiation of colorectal cancer5, 6,
with copy-number gains being mutually exclusive with P13K
pathway-activating mutations7. In addition over-expression of
H19-miR675 is frequently observed in colorectal cancers,
which suppress the expression of the tumor-suppressor RB18.
Downregulation of DIRAS3 (also known as ARH1) by either
deletion or methylation is frequently observed in breast and
ovarian cancers9, 10 and has been implicated in sensitivity to
Cisplatin, a widely used platinum-based chemotherapy agent11.
Furthermore epigenetic silencing and deletions of L3MBTL1, a
member of the polycomb-like family located at chromosome 20q,
is associated with hematological malignancies showing increased
genome instability12, 13.
Imprinted deregulation has also helped modify our thoughts
on the classical genetic events leading to cancer. For example,
despite the RB1 gene being at the center of Knudson’s two hit
hypothesis in which familial retinoblastoma displays autosomal
dominant inheritance with the first hit present in the germline
and the second somatically acquired14, this gene is preferentially
expressed from the maternal chromosome15. This is evident in
epidemiological data from sporadic retinoblastoma patients in
which the maternal chromosome 13 is preferentially lost16.
Ignoring placenta-specific imprinted genes17–19, there are
currently ~150 transcripts in the human genome mapping to ~30
domains suggesting that other imprinted genes may contribute to
the development of cancer in adults. However to date very few
studies have systematically looked at the influence of somatically
acquired copy-number alterations (CNAs) on imprinted methy-
lation profiles in cancer. We have performed an analysis to
determine the association between CNAs and DNA methylation
profiles for three cancer cell types originating in the lung,
colon and breast which rank among the most frequent
solid tumor types, as well as liver, which is a prevalent cause of
cancer-associated deaths due to hepatitis B virus infections
(https://www.cancer.org/research/cancer-facts-statistics). Overall
we observe that all four-tumor types show highly aberrant
profiles, with a high proportion of aberrant imprinted DMR
methylation patterns being associated with cancer-associated
CNAs and not somatically acquired epigenetic defects.
Results
We utilize copy-number and epigenetic data from a large set of
cancer cell lines from the Sanger Institutes COSMIC project20, 21
with observations confirmed in cohorts of well-characterized
primary cancer samples from The Cancer Genome Atlas (TCGA)
consortium7, 22–25. To determine the interplay between CNAs
and DNA methylation we combined data from genotyping
(Affymetrix Genome-wide SNP6 arrays) and methylation
(Illumina Infinium HumanMethylation450 BeadChips, HM450k)
platforms that interrogated 906,000 single-nucleotide poly-
morphisms (SNPs) and 485,577 CpG dinucleotides, respectively.
Our group has previously characterized the Infinium HM450k
methylation array for parent-of-origin methylation associated
with imprinted regions17. In this study we focused on the 661
probes mapping to 37 imprinted DMRs.
CNAs at imprinted domains in cancer cell lines. High-
resolution copy-number data for each imprinted domain was
obtained from COSMIC cell line project that included 173 lung,
50 colorectal, 49 breast and 15 hepatocarcinoma cell lines.
We confirmed the CNAs using other low-resolution molecular
cytogenetic methods, including SKY karyotyping and standard
DNA fluorescence in situ hybridization (FISH) (Fig. 1a–c)(http://
www.pawefish.path.cam.ac.uk)25. We identify thousands of
aberrations including deletions, amplifications and cnnLOH.
Copy-number calling was reported as total copy number and
minor allele, where a normal diploid state is 2:1 and cnnLOH
having a total copy number≥ 2 and a minor allele count of zero,
an event in which one allele is deleted and the remaining one
amplified. In all cases an estimated ploidy baseline (total alleles/
baseline ploidy) was also calculated for each cell line (Supple-
mentary Data 1 and Supplementary Figs 1–6) since total copy
number≥ 2 could represent amplification in a diploid tumor but
a deletion in a hyperploid tumor. No cell lines had normal copy-
number at all imprinted domains, with the least affected being the
breast-derived CAL-51 cell line that was normal except for
cnnLOH of the chromosome 11q15 domains (2:0) and the col-
orectal cell line LS-180 which had isolated cnnLOH of GRB10
(2:0). The most severe CNAs were observed in lung cancer cell
lines, with the PPIEL locus on chromosome 1 being amplified up
to 14 times in DMS-273 (14:1) NCI-H378 (14:1) and NCI-H1836
(14:2) with the NCI-H1694 cell line having all copies of one allele
(14:0). Such huge gains were not restricted to the PPIEL locus as
the MCTS2/HM13 domain was also amplified 14 times in the
SKLU-1 cell line (14:2). The full catalog of copy-number and
methylation results is available at www.humanimprints.net
(Supplementary Data 2).
Next, we wish to determine the size of the CNAs since
telomere/centromere bound aberrations tend to be larger than
focal internal CNAs24. Indeed we observe that focal internal
CNAs incorporating imprinted domains were smaller in 96% of
cases and were in higher copy number 79% of the time. For
example the average telomere bound amplification for HTR5A on
chromosome 7 is 41Mb, with an average total copy-number of
4.4, whereas internal amplifications are on average 8.5 Mb with
>9 copies (Supplementary Data 3). For chromosomes harboring
more than one imprinted domain, the CNAs may be focal or
involve the entire chromosome arm (Fig. 1c, d)(extended data
available at the www.humanimprints.net). This was confirmed
using DNA FISH in the breast cancer cell line HCC1954 that has
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an internal amplification of 15q11.2-12 including SNRPN that
does not encompass the nearby centromere (Fig. 1c).
CNAs dictate imprinted DMR methylation profiles. We hypo-
thesize that CNAs are a major determinant of allelic methylation
at imprinted DMRs. To ensure that the profiles obtained using the
COSMIC HM450k methylation data set accurately reflected the
methylation pattern at imprinted DMRs, we compared the profiles
for five cell lines with those obtained using reduced representation
bisulphite sequencing (RRBS) generated by ENCODE. Despite the
difference in technology, a comparison of the methylation profiles
revealed high correlation (Spearman ‘s correlation: A549 r= 0.85,
HCT-116 r= 0.79, T47D r= 0.95, HepG2 r= 0.6, MCF7 r= 0.74.
P-value< 0.0001) suggesting that the HM450k methylation array
data can be used with high confidence (Supplementary Fig. 7). To
test our hypothesis, we subsequently compared the absolute
methylation (average methylation for all probes within an
imprinted DMR) with the CNA-based predicted methylation
value. Assuming that no epimutations have occurred, then
methylation will be entirely dictated by chromosome number and
parental origin. For example for a normal cell with 2:1 copy-
number complement, methylation will be ~ 50% as one allele is
methylated and the other unmethylated. However for a cell line of
4:1, depending on the parental origin of the minor allele methy-
lation will be in a ratio of 75:25 or 25:75%. In all cases of cnnLOH
the methylation profile will be near zero or fully methylated
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Fig. 1 Analysis of copy-number and methylation of imprinted regions in cancer cell lines. a A Circos graph showing the average methylation for probes mapping
within each imprinted DMR for the breast cancer cell line MDA-MB-453. The center heatmap represents the methylation profile obtained from the Illumina
Infinium HM450k methylation BeadChip array of 19 normal breast samples, whereas the outer heatmap represent the profile of the cell line. The outer section
represents the average copy number for each imprinted loci, obtained from Affymetrics SNP6 array data, depicted as minor allele count (light blue) and total
copy number (dark blue). b Sky karyotype validation for the same cell line revealing near tetraploid status. c Standard DNA FISH analysis for the chromosome
15q11-13 region in three cell lines. The red probe maps ~1Mb from SNRPN in the GABRB3 gene, while the green probe maps to the centromere. The colorectal cell
line HCT-15 has normal copy-number, whereas the two breast cancer cell lines carry CNAs. The HCC1954 cells have a focal amplification of SNRPN while the
amplification in the T47D cells incorporates the centromere. d A chromosome ideogram showing the extent of amplifications and deletions for the SNRPN and
IGF1R domains on chromosome 15. Amplifications are in red and deletion in blue with the width of the lines representing the total copy-number for each
aberration. e The observed vs. expected methylation profile for the PPIEL domain in lung-derived cancer cell lines. The dashed lines represent the± 3 s.d. of the
mean of normal control tissues. Data points outside this range are deemed to have a methylation profile independent of CNA
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irrespective of the total chromosome number. Any sample with a
CNA-based predicted methylation value outside± 3 s.d. of normal
tissue controls were assumed to have a profile not dependent on
CNA, and attributed to a failure to maintain the correct epigenetic
profile (Fig. 1e). In total 17.6% of all imprinted DMRs in breast-
derived cancer cell lines present with methylation changes inde-
pendent of CNA, whereas only 12.8% lung, 9% liver and 8.1%
colon cancer cell posses methylation profiles not corresponding to
copy-number. An estimate of the proportion of methylation
variability explained by copy-number alone is shown in the
supplementary information (Supplementary Fig. 8). The most
frequently epimutated regions varied depending on tissue origin,
with the maternally methylated ZNF597 DMR being affected in
66.6% of hepatocarcinoma cell lines, H19 in 28.9 % of lung,
ZNF331 DMR1 in 32% of colon and GRB10 in 44.9% of breast-
derived cancer cell lines.
Methylation profiling at copy-number normal loci. To obtain a
clearer picture of the role of aberrant methylation independent of
CNAs, we assessed the allelic methylation asymmetry at
imprinted domains in cancer cell lines without copy-number
changes. A comparison of the distribution of Infinium HM450k
β-values revealed that copy-number normal samples were more
frequently hypermethylated rather than failing to maintain
methylation, a pattern that was not obvious when all cell lines
were analyzed together irrespective of CNAs (Fig. 2a). To confirm
the high-density array methylation profiles we performed
pyrosequencing for 3 DMRs including NHP2L1, FAM50B and the
KvDMR1 (Fig. 2b). The results obtained were extremely similar
for the two different methodologies (Spearman’s correlation;
NHP2L1 r= 0.88, FAM50B r= 0.97, KvDMR1 r= 0.88), further
reassuring us that the array-based methylation profiling
is extremely accurate. However, despite being quantitative,
pyrosequencing does not give strand-specific or allelic informa-
tion and averaging β-values for all probes within an imprinted
DMR may mask subtle anomalies. For these reasons, we
performed bisulphite PCRs and subcloning to confirm some of
the rare unexpected array methylation profiles (Fig. 2c). For
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Fig. 2 Methylation anomalies at imprinted DMRs in cancer cell lines. a Line graphs of the number of cancer cell lines showing methylation defects in
imprinted DMRs. Control DNA methylation frequencies are depicted by black solid line with a β-values near 0.5 indicative of one methylated and one
unmethylated allele. Dashed line represents total methylation defects irrespective of the underlying CNA status, whereas solid red line represents the
methylation profiles in samples carrying normal 2:1 copy number complement. b Pyrosequencing quantification for the NH2PL1 and FAM50B DMRs in
colorectal cell lines with different CNA status. The average methylation of eight controls colon biopsies were used to generate Turkey box-and-whisker
plots with whiskers spanning from 25th to 75th percentiles± 1.5 interquartile range to highlight outliers. A similar analysis was performed for the KvDMR1
in lung cancer cell lines. Number of copies is represented by circle size (inner, minor allele; outer, total copy number). c Detailed methylation maps of four
imprinted DMRs as determined by Illumina Infium HM450k methylation beadChip arrays. Each dot represent the position of single probes with the profiles
of cancer cell lines (red data points) compared to the respective normal tissues (black data points). The green bars highlight the position of the CpG islands
associated with each DMR and the arrow the nearest transcripts. Two different bisulphite PCRs were performed per region to confirm the strand-specific
methylation profile as determined by cloning and direct sequencing. Each circle represents a single CpG dinucleotide on a DNA strand (results for multiple
DNA strands are depicted as rows), filled circles indicate a methylated cytosine, and open circles an unmethylated cytosine
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-017-00639-9
4 NATURE COMMUNICATIONS |8:  467 |DOI: 10.1038/s41467-017-00639-9 |www.nature.com/naturecommunications
example we observe complete hypermethylation at the PLAGL1
DMR in the colorectal cell line SW48 but two different profiles in
SW837, with the 5′ promoter region being fully methylated whilst
the interval encompassing the transcription start site (TSS) has
normal allelic methylation. A similar bipartite methylation profile
was also observed at the MEG3 DMR in the hepatocarcinoma cell
line JHH-4. In addition we observe normal allelic methylation of
the L3MBTL1 DMR in breast cancer cell line T47D, with the
exception that the ~ 200 bp immediately adjacent to the TSS,
which is devoid of methylation. We previously described that the
bidirectional promoter associated with the SGCE and PEG10 is a
maternal DMR on the telomeric side of a large CpG island, with
the opposite side unmethylated in all somatic tissues, except
placenta where is also methylated on the maternal allele17.
Intriguingly we observe that several cell lines, irrespectively of
tissue origin, adopt this placenta profile, which we confirm by
PCR in the hepatocellular carcinoma cell line HepG2 (Fig. 2c).
The influence of nearby non-imprinted genes within CNAs.
The effect of non-imprinted genes located within the same CNAs
as imprinted loci could influence tumor development. In an
attempt to understand the impact of additional genes, we
identified nine oncogenes and two tumor-suppressor genes
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that map within the vicinity of the imprinted loci (Supplementary
Data 4). In general, the greater the distance between the
cancer-associated gene and the imprinted loci the lower the
frequency that both regions are involved in the same cytogenetic
aberration. However, in many cases both loci are affected. For
example, the imprinted PPIEL locus is located ~373 kb from the
MYCL1 oncogene and co-amplification of both regions was
observed in 98% of lung, 91% in liver, 97% in breast and 100% in
colon cancer cell lines harboring copy-number gains of 1p34.
In addition to the classic acquired LOH caused with deletions,
we show that cnnLOH is a common chromosomal defect
affecting imprinted loci. Since cnnLOH may lead to homo-
zygosity of pathogenic mutations (i.e., silencing tumor-suppressor
genes or activating oncogenes) we screened for genes with
homozygous mutations mapping within cnnLOH regions harbor-
ing imprinted loci. Of the 280 cell lines analyzed, 258 had at least
one region of cnnLOH affecting an imprinted loci with 26% also
containing homozygous mutated genes described from in the
COSMIC database. The majority of mutated genes have not been
associated with tumor initiation of progression. However we did
identify reoccurring mutations of RB1 associated with cnnLOH of
chr13q14 and PTEN mutations with cnnLOH of chr10q23-26 in
lung and breast cancer cell lines (Supplementary Data 5).
Further analysis of the parent-of-origin of the cnnLOH, as
inferred by the methylation profile of the affected imprinted
DMRs, suggests that the influence on imprinted gene dosage is
complex. For example, cnnLOH for the chr11p15.5 interval
involves both the maternally and paternally derived chromo-
somes equally in breast and lung cancer-derived cell lines, but is
exclusively paternal in colon cancer cell lines consistent with
previous observations that IGF2 over-expression is oncogenic7.
For cases also harboring homozygous mutated genes, it seems
that the presence of the genetic variant is more influential than
the parent-of-origin of the cnnLOH, with the exception that RB1,
in which all lung cancer cell lines (7/7) are associated with
hypermethylation at the RB1 imprinted DMR.
DMR profiles are independent of other epigenome changes.
Compared to normal cells, cancer cells show drastic changes
in DNA methylation status, generally exhibiting global hypo-
methylation at intragenic and repetitive elements accompanied by
regions of hypermethylation. Over the years the various regions of
cancer-associated hypermethylation have been defined, initially as
a collective of promoter CpG islands prone to gaining methylation
known as CpG island methylator phenotype (CIMP)26. The list of
hypermethylated regions is continually expanding with use of
technologies with increased genome resolution and now include
bivalent domains, CpG-rich sequences decorated with the
permissive histone modification H3K4me2/3 and the repressive
modification H3K27me3, which represent ~68% of cancer-
associated hypermethylated genes27, 28 and DNA methylation
valleys (DMVs), large intervals that are generally devoid of DNA
methylation in normal tissues29 (Supplementary Data 6). We
compared the DNA methylation profiles of 30 CIMP, 442 bivalent
domains and 166 DMVs to obtain a general genome methylation
profile in each cancer cell line. We observe that cell lines with the
greatest number of hypermethylated CIMP regions were also more
susceptible to bivalent and DMV hypermethylation (Fig. 3a). To
determine if the predominant hypermethylation we observe at
imprinted DMRs simply reflects the genome-wide methylation
state, we ordered each cell line according to its CIMP profile (i.e.,
ranked according to the severity and number of affected loci per
cell line). Unlike CIMP and bivalent domains that are highly
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correlated (Pearson’s correlation: colon r= 0.96. Spearman’s cor-
relation: breast r= 0.93, liver r= 0.92 and lung
r= 0.93) there was no apparent similarity between CIMP and
imprinted methylation for any cancer type (Fig. 3b).
In addition, we assessed a subset of cancer cell lines for
hypomethylation of repetitive DNA (ALU-Yb8, LINE-1 and
α-satellites). These elements are commonly used as surrogates to
measure genome-wide methylation levels as ~ 27% of total
CpG methylation is contained within LINE-1 elements and 23%
in ALU-Yb8 sequences30. We identified substantial hypomethyla-
tion of these elements in numerous cell lines compared to tissue
matched controls, but those cell lines affected did not show extreme
hyper- or hypomethylation at imprinted DMR (Supplementary
Fig. 9). Taken together these observations argue against a direct
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connection between global DNA methylation status and imprinting,
supporting an independent mechanism of regulation in cancer.
Allelic expression profiling in cancer cell lines. To date, very few
cancer cell lines have been assessed for allelic expression of
imprinted genes. To determine the influence of both methylation
and CNAs on allelic expression, we genotyped highly informative
exonic SNPs within NAPL1L5, PEG10, H19, IGF2, MEST,
KCNQ1OT1, MEG3, PEG3, L3MBTL1 and NHP2L1 in 57 cancer
cell lines with allelic expression determined by PCR with reverse
transcription (RT-PCR) in heterozygous cases (Supplementary
Figs 10–19). This revealed that if expressed, copy-number normal
cell lines with normal methylation maintained appropriate
monoallelic expression (e.g., NHP2L1 in NCI-H441; KCNQ1OT1
in COLO-824, DM-273, HCT-15, NCI-H1048 and MDA-MB-
157; MEG3 in Hs-578-T; NAP1L5 in BT-474, GP5d and
HCT-15; PEG10 in HCT-116) and in rare cases with robust
loss-of-methylation the transcripts were biallelically expressed
(e.g., NHP2L1 in HLE). Interestingly we observe several cases
in which cell lines with a total/minor ratio of 4:2 with ~50%
methylation are also robustly expressed from one genotype,
suggesting that the four chromosomes are maintaining their
original parental imprints having two active and two repressed
chromosome copies (e.g., NHP2L1 in Hs-578-T and NCI-H508,
KCNQ1OT1 in AU565 and HCC1954; H19 in LS-411N and
LS-1034; L3MBTL1 in NCI-H1975; NAP1L5 in MDA-MB-453).
To confirm these expression profiles, we performed RNA FISH
for the long non-coding (lnc)RNA KCNQ1OT1 that is retained
near the site of transcription. In the breast cell line COLO-824, we
observe a single signal consistent with it being copy-number
normal and monoallelically expressed, as did the colorectal cell
lines HCT-15, confirming the observations by Sunamura et al.31
(Fig. 4a, b and Supplementary Fig. 20). We observe two signals in
the MCF7 cell line that has cnnLOH for 11p15 (total/minor ratio
of 2:0) and absence of methylation at the KvDMR1. Interestingly
we also observe two KCNQ1OT1 signals in the copy-number 4:2
HCC1954 cell line consistent with two copies of the paternal
allele being expressed in these cells. These observations highlight
that fact that a cell may be transcribing from more than one
chromosome but maintaining the correct imprinting profile if it
carries copy-number aberrations.
Confirming imprinted CNAs in primary cancer samples.
Human cancer-derived cell lines are widely used models to study
the biology of cancer and in the majority of cases recurrent
genetic and epigenetic change found in tumors are also identified
in cell lines and vice versa. In order to confirm our cell
lines observations in primary tumors we analyzed publically
available data sets from TCGA including breast carcinomas
(BRCA), colon adenocarcinomas (COAD), liver hepatocellular
carcinomas (LIHC) and lung tumors (lung adenocarcinomas,
LUAD + squamous cell carcinomas, LUSC) for which data is
available from normal, tumor and adjacent-tissue samples.
A huge number of CNAs were observed in the primary
data sets encompassing imprinted domains, but in most cases
copy-number gains were not as severe as in cell lines and were
restricted to the tumor samples and not matched adjacent-tissue
(Fig. 5a, b). For many imprinted loci the copy-number
aberrations were a mix of both deletions and amplifications, but
striking recurrent changes were observed. For example, the four
imprinted regions on chromosome 20q (MCTS2, NNAT,
L3MTBL1 and GNAS) were invariable subject to copy-number
gains with very few deletions observed in the four cancer types. In
contrast some imprinted domain were associated with CNAs
specific to a tumor type. When observed, H19/IGF2 CNAs in
COAD were mainly amplifications, consistent with previous
reports7, whereas equal numbers of gains/losses are observed in
the other three tumor types analyzed. Furthermore, amplifica-
tions of RB1 at chr13q14 were preferentially observed in COAD
samples whereas deletions were preferentially observed in BRCA,
the latter consistent with the reports of the functional loss of
RB1 in basal-like and luminal breast carcinomas32. Similarly
chromosome 22q deletions are common somatic alteration in
both breast and colorectal cancer33 and we confirm a high
frequency of deletions of NH2PL1 mapping to 22q13 in BRCA
and COAD data sets.
Next, we wish to determine the size of the CNAs since we
observed that telomere/centromere bound aberrations tend to be
larger than focal internal CNAs in cancer cell lines. This was also
true for CNAs encompassing imprinted domains in primary
cancer samples, with focal internal CNAs being more prevalent
and often in higher copy number than those involving either
the telomere or centromere (extended data available at the
www.humanimprints.net). For example the average telomere
bound amplification for IGF1R on chromosome 15 is 18Mb,
often representing just a single additional copy, whereas internal
amplifications are on average 3Mb with 6–7 copies.
Imprinted methylation in TCGA data sets. The methylation
changes in the TCGA primary tumor samples are less frequent
and less extreme than in cancer cell lines; however, this
may reflect cellular composition of the sample with primary
tumors being heterogenous and infiltrated with normal cells
(mean tumor cell estimate± s.d.; BRCA 72.2± 20.5%, COAD
71.5± 16.6%, LIHC 87.1± 11.7%, LUAD 76.3± 19.1%) (Supple-
mentary Data 7).
There was high correlation between hypermethyalted CIMP,
bivalent domains and DMVs for all tissues (Spearman’s
correlation for CIMP vs bivalent domains: BRCA r= 0.88, COAD
r= 0.95, LIHC r= 0.81 and LUAD r= 0.84)(Fig. 5c), with the
Fig. 5 Methylation profiles of imprinted DMRs in primary TCGA cancer samples. a Scatter plots for imprinted domains on chromosome 20 in tumor,
adjacent and control somatic DNA reveals that the CNAs are restricted to the cancer samples. b Ideogram for chromosome 20 showing the extent of
amplifications and deletions for MCTS2, NNAT, L3MBTL1 and GNAS domains in lung-derived cancer samples. Amplifications are in red and deletion in blue
with the width of the lines representing the total copy-number for each aberration. c Stacked histograms ranked according to the severity and number of
affected loci per sample. The graphs in the left column reveal that cell lines with the highest hypermethylation burden for CIMP regions are similarly
hypermethylated at bivalent domains. The middle column is a comparison between the methylation profiles of imprinted DMRs irrespective of CNA status
and CIMP. The right row is the same comparison but with only imprinted domains with a normal copy-number. For each type of loci the number of genes
analyzed is indicated on the x-axis. d Line graph of the number of cancer samples showing methylation defects in imprinted DMRs. Control DNA
methylation frequencies are depicted by black solid line with a β-value near 0.5 indicative of one methylated and one unmethylated allele. Dashed red line
represents total methylation defects irrespective of the underlying CNA status, whereas solid red line represents the methylation profiles in samples
carrying normal 2:1 copy number complement. e The observed vs. expected methylation profile for the GNAS A/B DMR overlapping exon 1A in lung
tumors. The dashed lines represent the ± 3 s.d. of the mean of normal control tissues. Data points outside this range are deemed to have a methylation
profile independent of CNA
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COAD sample set being more hypermethyalted than the other
cancer types (Supplementary Data 8). With the exception of the
LIHC samples, the number of imprinted DMRs subject to
hypermethylation is much greater than those with hypomethyla-
tion (Fig. 5c, d), with no correlation with global DNA
methylation status as gauged by comparisons with CIMP, bivalent
domains and DMVs (Fig. 5c). Consistent with our observation in
cell lines, aberrant imprinted methylation was closely associated
with CNAs status (Fig. 5e). To determine whether specific
imprinted DMRs were affected in cancer from different tissue
origin, we assessed the frequency of methylation defects at loci
with normal 2:1 copy-number. No particular DMR was
affected in specific cancer type. The most frequently observed
hypermethylated regions are PEG13 (60%) in COAD, PPIEL
(34%) in LIHC, INPP5FV2 (30%) in BRCA and the paternally
methylated ZNF597 DMR (20%) in LUAD. Similarly, no
imprinted DMR was consistently hypomethylated, with the most
frequently affected regions being GNAS (20%) in LIHC, FAM50B
(9%) in LUAD, L3MBTL1 (8%) in COAD and MCTS2 (6%)
in BRCA. Furthermore some imprinted DMRs have stable
methylation comparable with normal tissues with the LUAD
data set having the most unaffected loci (NAP1L5, PLAGL1,
PEG10, MEST, PEG3, NNAT and NH2PL1).
Molecular subtypes and imprinted methylation. The somatic
load of driver mutations in the cancer cell lines has been extensive
studied, with the results cataloged in the COSMIC somatic
mutation database. To determine if methylation defects at
imprinted loci were more prevalent in tumors harboring-specific
genetic aberrations, we compare methylation profiles of samples
with 2:1 copy-number positive for common mutations1. We
failed to observe any association between reoccurring mutations
(TP53, PIK3CA, CDH1 and AKT1 in breast-derive cancer cell
lines; TP53, MLH1, APC, KRAS, BRAF and PIK3CA in colorectal
cancer cell lines; CTNNB1, TP53, AXIN1, JAK1 and LRP1B in
hepatocarcinoma cell lines; TP53, PIK3CA and AKT1 in lung
cancer cell lines) or microsatellite instability (MSI) and imprinted
DMR status for any cell lines. However we observe increased
normal copy-number status in colon, liver and lung-derived cell
lines with high MSI, consistent with the previous reports that
chromosomal instability and microsatellite stability are largely
mutually exclusive34 (Supplementary Figs 21–24).
The primary tumor samples from the TCGA have also been
extensive studied at the molecular level allowing similar
comparisons to be performed. Comparable to cell lines, we do
not observe increased frequency of aberrant imprinted methyla-
tion for any characteristic including reoccurring mutations,
hepatitis infections and alcohol consumption in LIHC, smoking
status in LUAD or HER2, progesterone or estrogen hormone
receptor status in BRCA data sets (Supplementary Figs 25–28).
Discussion
In this current study, we have generated DNA methylation and
CNAs profiles for over 280 cancer cell lines and compared the
results with large primary tumor data sets available from the
TCGA.
Methylation at imprinted loci is unique in that opposing
parental alleles have different methylations states that are dictated
by parental origin. Unlike other single-copy regions which may
be prone to accumulate cancer associated hypermethylation from
an initially unmethylated state, imprinted DMRs can either loose
or gain methylation. Importantly cancer-associated copy number
changes will influence the absolute methylation observed
at imprinted DMRs while this is not so important for CIMP,
bivalent domains and DMVs. In the majority of cases, we observe
that the methylation profiles at imprinted DMRs do not represent
epigenetic changes but simply the parental origin of underlying
CNAs. In some cases, we predict methylation errors may have
occurred within cytogenetically abnormal genomes, but it is not
possible to know which aberration, the CNA or methylation
defect, occurred first. In addition, it is impossible to know if all
copies of a highly amplified region for example PPIEL or GNAS
are subject to epimutations, resulting in a mosaic/clonal state.
It is known that some tumors with higher frequency of cancer-
associated hypermethylation are enriched for oncogenic
mutations. However our detailed analysis was unsuccessful in
revealing a clear link with any driver mutation or exposure.
Mutations in BRAFV600E35 and CTNNB136 have been described
in colorectal and liver tumors with extensively acquired
hypermethylation. We fail to identify any association between
aberrant imprinted methylation and these two mutations, despite
one study in hepatocellular carcinomas reporting enrichment
of CTNNB1 mutations in samples with hypomethylation at
imprinted loci37.
Direct evidence for the role of LOI and cancer comes from the
mouse model, in which biallelic expression of Igf2 present on an
Apc(Min) background has an increased incidence of colorectal
cancers38. However, human data implicating this locus in
sporadic cancer is more controversial. Biallelic expression of IGF2
has been associated with hypomethylation of the H19 DMR in
colorectal cancer39, rather than the hypermethylation that would
predictably lead to reactivation of the maternal allele of IGF2 by
ablation of insulator function. This hypomethylation extends to
the IGF2-DMR0 region and was reported to occur in the normal
colonic mucosa of patients, suggesting that this epigenetic
abnormality is not limited to the tumors. Methylation data from
TCGA COAD data set supports the observed hypomethylation at
both these paternally methylated DMRs (cg19642877 is the only
probe on the HM450k platform mapping within IGF2-DMR0
with methylation somatically acquired DMR, therefore this was
not included in our analysis) but there is no evidence for aberrant
methylation in adjacent normal tissues (Supplementary Data 9),
endorsing the reports that methylation at this regions is not a
predisposing constitution biomarker for colorectal cancer40.
Cultured cancer cell lines are widely used models and have help
form the fundamental basis for our current understanding of
cancer biology. However the use of such an in vitro system
has limitations. These include cell line misidentification41 and
inter-laboratory clonal expansion or induce secondary genomic
changes that may occur since these originally heterogeneous
cell lines have been maintained for decades in different culture
conditions. To limit these oversights, we have performed our
genotyping and methylation analyses on the same DNA samples
obtained from the Wellcome Trust Sanger Institute, with
quantitative and allelic conformation performed on these
DNA aliquots. Furthermore the results of our allelic expression
profiling are consistent with examples reported in literature. For
example, the methylation and allelic expression of DIRAS3 in the
breast cell lines UM159 and CAL51 as reported by Niemczyk
et al.42, and the H19 methylation profile of the colorectal cell
lines COLO-205 and LoVo are similar to those reported more
than 10 years ago43. We also observe identical hypermethylation
in the liver cancer cell lines at the RB1 (HLE and HuH-7) and
MEG3 DMRs (HLE and HuH-7)44–46 although our data suggests
that these profiles are due to cnnLOH.
While we are confident that our allelic expression results are
consistent with previous reports and reflect the expression status
in the cell lines, results are sometimes not as would be predicted.
For example in the colon cell line HCT-116, we observe robust
monoallelic expression despite the H19 DMR being methylated
on both alleles. This is further complicated by the fact that
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the nearby cis-regulated somatic IGF2-DMR0 maintains allelic
methylation consistent with previous reports39. In addition
the COLO-205 is heterozygous for the reciprocally imprinted,
co-regulated H19 and IGF2 genes. However, we observe a
discordant expression pattern with maintained monoallelic
expression of H19 and biallelic expression of IGF2, a situation
that has previous been reported in lung adenocarcinomas47. One
possible explanation for the latter observation is that expression
of IGF2 has switched from the predominant P3/P4 imprinted
promoters to the tissue-specific non-imprinted P1 promoter48.
A similar scenario may account for the biallelic expression of
MEST observed in many cell lines despite the DMR being
hypermethylated, however since the SNP used to discriminate
alleles is located beyond PCR range, we are unable to demonstrate
promoter switching.
To conclude, the involvement of imprinting in cancer has
gained much attention, but very few studies have taken CNAs
into account when reporting methylation profiles. This has
resulted in the inflated documenting of somatically acquired
epigenetic errors at imprinted loci in cancer. Our data strongly
suggest that CNAs should be investigated before reporting an
epigenetic change at imprinted loci in cancer.
Methods
DNA samples. Cell line DNA used for confirmation analyses were obtained
directly from the Sanger Institute. All cell lines cultured in-house, except two, were
obtained from ATCC repository and grown using conditions recommended by the
supplier. The hepatocellular carcinoma cell lines JHH-2 and JHH-449 were
obtained from the National Institute of Biomedical Innovation JCRB Cell Bank,
Osaka, Japan. These cells were maintained in Eagle’s minimal essential medium
plus 10% fetal bovine serum.
Control liver, breast, colon and lung tissue samples were obtained from
Catalan Tumor Biobank (http://www.clinicbiobanc.org/) with DNA extracted with
phenol/chloroform using phase-lock gel columns (5 Prime) and RNA extracted with
Trizol (Thermofisher) following standard protocols. cDNA synthesis was performed
using 1ug of RNA following an initial DNase treatment (amplification grade DNase I,
Invitrogen). Reverse transcription was performed with MMLV retrotranscriptase
(Promega) and random primers (Promega) following the manufacturer’s instructions.
Ethical approval for this study was granted by the Institutional Review Boards of the
Bellvitge Institute for Biomedical Research (PR223/09) and (PR024/11).
Bioinformatic analysis. The Illumina Infinium HM450k methylation data sets for
cancer cell lines and primary samples was obtained from COSMIC cell line project
(GEO number GSE68379) and TCGA Data Portal (https://tcga-data.nci.nih.gov),
respectively. Pre-processing and normalization were performed following
GenomeStudio (Illumina) using the Bioconductor minfi package50. This includes
background subtraction and control normalization. After normalization,
methylation beta (β) values range from 0 (unmethylated) to 1 (fully methylated).
Before analysis, we excluded possible sources of technical bias and genetic variation
that could influence results. We discarded, firstly, all probes with a detection
P-value> 0.01 in more than 10 % of the samples and secondly, those with missing
values in one or more of the tested samples. We also discarded those probes
containing a common SNP (minor allele frequency≥ 1%, dbSNP138) in the
flanking 5 bp of the interrogated CpG site. Finally, we removed all probes mapping
to the X and Y chromosomes. All analyses were performed using human genome
version 19 (hg19) as the reference genome. When applicable, coordinates from
hg18 to hg19 version were converted using LiftOver tool from USCS Genome
Browser website (https://genome.ucsc.edu).
Epigenetic profiles: Infinium HM450k probes located within bivalent
domain, DMV and CIMP regions were extracted according to published
coordinates26, 27, 29. For each sample the average β-value of the probes located
within each defined interval was calculated. For subsequent methylation analysis,
only regions that were uniformly unmethylated (<0.2 average β-value) in normal
tissues (n= 19 breast, n= 12 colon, n= 10 liver and n= 7 lung) were selected. We
categorized the intervals according to the severity of methylation gains as
compared to their corresponding normal tissue controls, being lowly methylated
(mean of controls + 0.2), mildly methylated (absolute β-value > 0.5) and highly
methylated (absolute β-value> 0.75).
Imprinted methylation analysis: Infinium HM450k probes located within 37
germline imprinted DMRs which have more than one probe were extracted from
loci defined by methyl-seq17. For each sample, the average methylation at each
imprinted DMRs was calculated. Briefly, we classified hyper/hypomethylated
imprinted DMR when averaged β-values are above or below 0.8/0.2. We also
calculated intermediate methylation defects when samples show ± 0.2 β-value
relative to controls, but the absolute methylation do not reach 0.8/0.2 cutoff values.
For each cancer type, methylation analyses for cell lines and TCGA samples were
performed independently using the same criteria. For TCGA data set, methylation
level of an individual tumor sample was compared to its corresponding non-tumor
adjacent-paired tissue, whereas methylation level for each cancer cell line was
compared to the averaged β-values of corresponding normal tissue controls.
RRBS methylation analysis. Processed-RRBS data for A549, T47D, MCF7,
HCT-116 and HepG2 cell lines were downloaded from ENCODE project51
(GEO accession number: GSE27584). At each CpG site, the methylation rate was
calculated as the ratio of methylated reads (C) over the total read count (C + T) at
that site. Similar to Infinium HM450k data, CpG sites within imprinted DMRs
were extracted according to coordinates17 and the average methylation at each
imprinted DMR was calculated using RRBS-detected cytosines covered by≥ 10
reads. The association between methylation level at imprinted DMRs obtained
from Infinium HM450k and RRBS methods was assessed using Spearman’s
correlation coefficient.
Predicted methylation analysis: we obtained Affymetrix Genome-wide SNP6.0
genotyping profile of 287 cancer cell lines and 2676 TCGA primary tissues from
the Sanger Institutes COSMIC cell line project and TCGA data portal. A total of
306 cancer cell lines (derived from 51 breast cancers, 54 colorectal cancers;
20 hepatocarcinomas and 181 lung tumors) had Infinium HM450k array data,
allowing us to determine the association between CNAs and DNA methylation. At
the time of this study (2013 onwards) only 178 TCGA primary tissues had pair
data copy-number and methylation data. To obtain the CNA predicted
methylation value we first determined the minor methylation value as the ratio
between the minor and the total allele count. Then, if this corresponded to an
Infinium HM450k value below 0.5, we assume that the methylated allele was the
minor one and reported the minor methylation value as the CNA predicted
methylation. If the corresponding Infinium HM450k value was above 0.5, we
assumed that the methylated allele was the major one and report 1—minor
methylation value as the CNA predicted methylation.
To estimate the proportion of methylation variance explained by copy-number
we used univariate linear regression. For each imprinted region and tissue type, we
fit a model with the average observed methylation as outcome and the expected-by-
copy-number methylation (described above) as predictor, considering the different
cell lines as observations and obtaining the corresponding coefficient of
determination (R2).
CNA analysis: We used Level 3 CNA estimations for TCGA samples (BRCA
n = 1044; COAD n= 429; LIHC n= 208; LUAD n= 494 and LUSC n = 501). For
the cell lines, we used the CONAN copy number estimations. CNAs were
selected if they overlapped an imprinted DMR by at least 1 bp. We defined an
amplification/deletion to be internal if it was more than 1Mb away from the
corresponding telomere/centromere (whichever is closer). For TCGA data, we
utilized all available data (even if no methylation data was available) and estimated
copy number using circular binary segmentation algorithm as implemented in
PSCBS52.
Mutation status in cancer cell lines: We obtained mutational data for all cell
lines from the repository Cell Line Project release v76 (http://cancer.sanger.ac.uk/
cell_lines).
Genotyping and imprinting analysis. Exonic SNPs (minor allele frequency > 0.1)
within imprinted transcripts were identified in the UCSC hg19 browser and gen-
otypes obtained by PCR and direct sequencing. Sequence traces were interrogated
using Sequencher v4.6 (Gene Codes Corporation, MI). Heterozygous sample were
analyzed for allelic expression using RT-PCR incorporating the polymorphism
within the final PCR amplicon (for primer sequences see Supplementary Data 10).
Bisulphite PCR of cell line-derived DNA. For confirmation of methylation
profiles in normal tissues and cancer cell lines standard bisulphite conversion of
approximately 1 μg DNA was subjected to sodium bisulphite treatment and
purified using the EZ DNA methylation-Gold kit (ZYMO, Orange, CA).
Approximately 2 ul of converted DNA was used in each amplification reaction
using Immolase Taq polymerase (Bioline) at 45 cycles and the resulting PCR
product cloned into pGEM-T easy vector (Promega) for subsequent subcloning
and sequencing (for primer sequence see Supplementary Data 10).
Pyrosequencing analysis for methylation quantification. Approximately 50 ng
of bisulphite converted DNA was used for pyrosequencing of imprinted DMR or
repeat elements30, 53. Standard bisulphite PCR was used to amplify the regions of
interest with the exception that one primer was biotinylated (for primer sequences
see Supplementary Data 10). For sequencing, forward primers were designed to
the complementary strand. The pyrosequencing reaction was carried out on a
PyroMark Q96 instrument. The peak heights were determined using Pyro
Q-CpG1.0.9 software (Biotage). The data were subjected to statistical analysis using
Graph Pas Prism 5.0 (Graph Pad Software). Difference between groups were
considered significant at P< 0.05.
DNA FISH. The detection of CNAs involving 15q11-13 was identified using Vysis
probes with GABRB3 labeled with SpectrumOrange and the D15Z1 CEP15 labeled
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with SpectrumGreen (Abbott Molecular Inc.). For the preparation of metaphase
spreads, cell lines were exposed to colcemid for 3 h ~24 h after feeding. After
treatment with hypotonic solution the cells were fixed in Carnoy’s fixative dropped
onto glass slides. Prior to hybridization the slides were dehydrated through an
ethanol series of 70, 85 and 100% for one minute each. Heat denaturation,
hybridization in humidified chambers and washes were performed following
supplier’s recommendations. DAPI-vectorshield mounted slides were visualized
with on a Zeiss microscope with images of individual nuclei captured using the
automated MetaSystems platform.
RNA FISH. Expression of the lncRNA KCNQ1OT1 assessed by RNA FISH. Cells
were grown on poly-L-lysine coated slides and fixed in 4% paraformaldehyde-PBS
for 20 min at room temperature, washed twice in PBS and permeabilized with 70%
EtOH at 4 °C overnight. The fixed slides were washed twice in PBS, followed by two
washes in 2× SSC. Control slides were treated with RNAse A (Roche) treatment for
1 h at 37 °C and subsequently washed twice in 2× SSC. A pre-hybridization step
involving incubating the fixed slides in 15% formamide/2× SSC for 20 min at room
temperature was performed before hybridization. BAC probe RP11-937O11
(obtained from the BACPAC Resource Center) was labeled with either
SpectrumRed or SpectrumGreen UTP by nick translation and competed with
human COT-1 DNA (Roche) following the supplier’s protocol (Abbott Molecular
Inc.). 4 ul of heat denatured probe/LSI buffer was added to non-denatured slides
and hybridized overnight at 37 °C in a humidified chamber. Subsequently the slides
were carefully washed in 2× SSC/15% formamide for 20 min at 37 °C, followed
by two washed in 1× SSC at 37 °C for 20 min each. Slides were mounted using
DAPI-vectorshield and visualized using a Leica fluorescence microscope. A total of
100 nuclei were counted to determine the number of expression foci per cell.
Data availability. The Illumina Infinium HM450k methylation array and RRBS
methylation data sets for cancer cell lines were obtained from Gene Expression
Omnibus (GEO) accession numbers GSE68379 and GSE27584, respectively. Circus
graphs for methylation and copy-number as well as maps for the extent of
amplifications and deletions for all cell lines is available at www.humanimprints.
net.
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